Skip to content

Released Feb 27, 2012, after the close

10-K filed Feb 27, 2012, 58 days after period end · 0001144204-12-011082

Q4 2011 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$2.36Mderivedno prior Q4 2010 on file+108.7% vs Q3 2011
Net Income-$8.91Mderivedno prior Q4 2010 on fileN/M vs Q3 2011
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$294,000—
Operating Incomederived-$8,858,000—
Operating Cash Flowderived-$6,612,000N/M
Free Cash Flowderived-$7,316,000N/M
Margins · derived
Gross margin12.4%
Operating margin-375.0%
Net margin-377.3%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2011derived from reported figuresQ4 2010derived from reported figures
Revenue$2.36M—
Net Income-$8.91M—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR